KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.

The steady erosion of experienced staff is slowly compromising FDA work and low morale is pushing more workers to the exit ...

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Citizen’s Petition Filed Requesting FDA Approve NurOwn™ On July 3, 2025, a Citizen’s Petition was filed with the U.S. Food and Drug ...

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...

WILMINGTON, DE, UNITED STATES, July 7, 2025 /EINPresswire.com/ -- Stellar Market Research examines the growth rate of the Nicotine Pouch Market during the forecasted period 2025-2032 The Nicotine ...